MIrati Therapeutics, Iovance Biotherapeutics, and Personalis are all using genetic knowledge to help find cures for cancer.
News & Analysis: Iovance Biotherapeutics, Inc.
Good news from the biotech's mid-stage clinical study is exciting investors.
IOVA earnings call for the period ending September 30, 2019.
The company is flush with cash and wields a promising therapeutic pipeline. Is its recent tumble a buying opportunity?
IOVA earnings call for the period ending June 30, 2019.
These three biotech stocks might be outstanding buys right now.
The clinical-stage biopharma announced promising data at a major conference.
These three healthcare stocks could be outstanding additions to your portfolio.
Pfizer's acquisition of Array appeared to cause investors to wonder whether a big deal could be in store for Iovance.
Could the second half of the year be as much fun as the first?